Latest News and Press Releases

Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-associated cardiomyopathy.

Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults.AD begins with...

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.

Extracellular ASC has a crucial role in aggregation and deposition of amyloid A fibrils leading to associated chronic inflammatory conditions.

WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...

Inflammasome ASC Inhibitor IC 100 Reduced Inflammation and Restored Retinal Structure and Function in Retinopathy of Prematurity Animal Model

NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.

In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.

Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.